Predictive value of serum amyloid a levels for requirement of concomitant methotrexate in tocilizumab initiation: A post hoc analysis of the SURPRISE study

References

• Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M. Eular recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–77.
   PubMed Web of Science ®Google Scholar
• Emery P, Sebba A, Huizinga TW. Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Ann Rheum Dis. 2013;72:1897–904.
   PubMed Web of Science ®Google Scholar
• Mariette X, Gottenberg JE, Ravaud P, Combe B. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology (Oxford). 2011;50(1):222–9.
   PubMed Web of Science ®Google Scholar
• Pappas DA, Reed GW, Saunders K, John A, Shewade A, Greenberg JD, et al. Characteristics associated with biologic monotherapy use in biologic-naive patients with rheumatoid arthritis in a us registry population. Rheumatol Ther. 2015;2(1):85–96.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kremer J, Cush J, Rigby W, Teng LL, Devenport J, et al. Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study. Arthritis Care Res. 2013;65(3):362–71.
   PubMed Web of Science ®Google Scholar
• Dougados M, Kissel K, Conaghan PG, Mola EM, Schett G, Gerli R, et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the act-ray study. Ann Rheum Dis. 2014;73(5):803–9.
   PubMed Web of Science ®Google Scholar
• Bykerk VP, Ostor AJ, Alvaro-Gracia J, Pavelka K, Roman Ivorra JA, Graninger W, et al. Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice. Clin Rheumatol. 2015;34(3):563–71.
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Atsumi T, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, et al. Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (surprise study). Ann Rheum Dis. 2016;75(11):1917–23.
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The premier study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26–37.
   PubMed Web of Science ®Google Scholar
• Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the go-forward study. Ann Rheum Dis. 2009;68(6):789–96.
   PubMed Web of Science ®Google Scholar
• Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (adacta): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381(9877):1541–50.
   PubMed Web of Science ®Google Scholar
• Buckley F, Finckh A, Huizinga TW, Dejonckheere F, Jansen JP. Comparative efficacy of novel dmards as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional dmards: a network meta-analysis. JMCP. 2015;21:409–23.
   PubMedGoogle Scholar
• Kaneko Y, Kato M, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, et al. Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the surprise study). Ann Rheum Dis. 2018;77(9):1268–75.
   PubMed Web of Science ®Google Scholar
• Pers YM, Fortunet C, Constant E, Lambert J, Godfrin-Valnet M, De Jong A, et al. Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice. Rheumatology (Oxford). 2014;53(1):76–84.
   PubMed Web of Science ®Google Scholar
• Diaz-Torne C, Ortiz MDA, Moya P, Hernandez MV, Reina D, Castellvi I, et al. The combination of il-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab. Semin Arthritis Rheum. 2018;47(6):757–64.
   PubMed Web of Science ®Google Scholar
• Uno K, Yoshizaki K, Iwahashi M, Yamana J, Yamana S, Tanigawa M, et al. Pretreatment prediction of individual rheumatoid arthritis patients' response to anti-cytokine therapy using serum cytokine/chemokine/soluble receptor biomarkers. PLoS One. 2015;10(7):e0132055.
   PubMed Web of Science ®Google Scholar
• Okano T, Inui K, Tada M, Sugioka Y, Mamoto K, Wakitani S, et al. Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the petite (predictors of effectiveness of tocilizumab therapy) study. Rheumatol Int. 2016;36(3):349–57.
   PubMed Web of Science ®Google Scholar
• Izumi K, Kaneko Y, Hashizume M, Yoshimoto K, Takeuchi T. Baseline serum osteopontin levels predict the clinical effectiveness of tocilizumab but not infliximab in biologic-naive patients with rheumatoid arthritis: a single-center prospective study at 1 year (the keio first-bio cohort study). PLoS One. 2015;10(12):e0145468.
   PubMed Web of Science ®Google Scholar
• Matsuno H. Remarkable efficacy of tocilizumab for treating rheumatoid arthritis in patients with high platelet counts. Mod Rheumatol. 2015;25(1):38–42.
   PubMed Web of Science ®Google Scholar
• Kojima T, Yabe Y, Kaneko A, Takahashi N, Funahashi K, Kato D, et al. Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study. Rheumatology (Oxford). 2015;54(1):113–20.
   PubMed Web of Science ®Google Scholar
• Ye RD, Sun L. Emerging functions of serum amyloid a in inflammation. J Leukoc Biol. 2015;98(6):923–9.
   PubMed Web of Science ®Google Scholar
• Hwang YG, Balasubramani GK, Metes ID, Levesque MC, Bridges SL Jr, Moreland LW. Differential response of serum amyloid a to different therapies in early rheumatoid arthritis and its potential value as a disease activity biomarker. Arthritis Res Ther. 2016;18:108.
   PubMed Web of Science ®Google Scholar
• Shen C, Sun XG, Liu N, Mu Y, Hong CC, Wei W, et al. Increased serum amyloid a and its association with autoantibodies, acute phase reactants and disease activity in patients with rheumatoid arthritis. Mol Med Rep. 2015;11(2):1528–34.
   PubMed Web of Science ®Google Scholar
• Connolly M, Mullan RH, McCormick J, Matthews C, Sullivan O, Kennedy A, et al. Acute-phase serum amyloid a regulates tumor necrosis factor alpha and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy. Arthritis Rheum. 2012;64(4):1035–45.
   PubMed Web of Science ®Google Scholar
• Deetman PE, Bakker SJ, Dullaart RP. High sensitive c-reactive protein and serum amyloid a are inversely related to serum bilirubin: effect-modification by metabolic syndrome. Cardiovasc Diabetol. 2013;12(1):166.
   PubMedGoogle Scholar
• Hachulla E, Saile R, Parra HJ, Hatron PY, Gosset D, Fruchart JC, et al. Serum amyloid a concentrations in giant-cell arteritis and polymyalgia rheumatica: a useful test in the management of the disease. Clin Exp Rheumatol. 1991;9(2):157–63.
   PubMed Web of Science ®Google Scholar
• Yamada T, Okuda Y, Takasugi K, Itoh K, Igari J. Relative serum amyloid a (saa) values: the influence of saa1 genotypes and corticosteroid treatment in Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2001;60(2):124–7.
   PubMed Web of Science ®Google Scholar
• Satomura K, Torigoshi T, Koga T, Maeda Y, Izumi Y, Jiuchi Y, et al. Serum amyloid a (saa) induces pentraxin 3 (ptx3) production in rheumatoid synoviocytes. Mod Rheumatol. 2013;23(1):28–35.
   PubMed Web of Science ®Google Scholar
• O'Hara R, Murphy EP, Whitehead AS, FitzGerald O, Bresnihan B. Local expression of the serum amyloid a and formyl peptide receptor-like 1 genes in synovial tissue is associated with matrix metalloproteinase production in patients with inflammatory arthritis. Arthritis Rheum. 2004;50:1788–99.
   PubMed Web of Science ®Google Scholar
• Ogata A, Tanaka Y, Ishii T, Kaneko M, Miwa H, Ohsawa S, et al. A randomized, double-blind, parallel-group, phase iii study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: results of the 12-week double-blind period. Mod Rheumatol. 2018;28:76–84.
   PubMed Web of Science ®Google Scholar
• Genovese MC, van Adelsberg J, Fan C, Graham NMH, van Hoogstraten H, Parrino J, et al. Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to mtx: safety, efficacy and radiographic outcomes. Rheumatology (Oxford). 2018;57(8):1423–31.
   PubMed Web of Science ®Google Scholar
• Sokolove J, Schiff M, Fleischmann R, Weinblatt ME, Connolly SE, Johnsen A, et al. Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the ample trial. Ann Rheum Dis. 2016;75(4):709–14.
   PubMed Web of Science ®Google Scholar
• Cappelli LC, Palmer JL, Kremer J, Bingham CO. Tocilizumab treatment leads to improvement in disease activity regardless of ccp status in rheumatoid arthritis. Semin Arthritis Rheum. 2017;47(2):165–9.
   PubMed Web of Science ®Google Scholar